Biosafety

Biosafety Submission Guidelines

All personnel listed on IBC protocols must undergo training.

They must review and understand the following two required educational documents

Meetings are held on the fourth Tuesday of the month. Materials are due by the 15th of the month.

Meeting Minutes

April 28, 2026

March 24, 2026

February 24, 2026

January 27, 2026

December 23, 2025

November 25, 2025

October 28, 2025

September 23, 2025

August 26, 2025

July 22, 2025

June 24, 2025


Name 

Department

Representative Capacity

Nicholas Carpino, Chair

Microbiology and Immunology

Scientist

Kimberly Bowe

Biochemistry, Molecular biology and

Biotechnology

Non-Affiliated Member

Rachel Brownlee

Division of Laboratory Animal Resources

Veterinarian/ Animal
Representative

Jeronimo Cello

Microbiology and Immunology

Scientist

Jorge Escobar

Environmental Health and Safety

Scientist

Hwan Kim

Microbiology and Immunology

Scientist

Christopher Kuhlow

Environmental Health and Safety

Scientist

Natalie Osorio

Laboratory Technician (Chemistry)

Laboratory Representative

Non-Scientist

Dafang Faith Wang

Plant Biology

Plant Representative

Non-Affiliated Member

Question Answer

What is the role of the Institutional Biosafety Committee (IBC)?

The IBC is responsible for monitoring and ensuring compliance as well as review and approval of all research projects that involve biological material including rDNA materials and human gene therapy/gene transfer protocols.

.

What are Biosafety Levels (BSLs)?

According to the Center for Disease Control, there are four biosafety levels. Each level has specific controls for containment of microbes and biological agents. The primary risks that determine levels of containment are infectivity, severity of disease, transmissibility, and the nature of the work conducted. Origin of the microbe, or the agent in question, and the route of exposure are also important.

Each biosafety level has its own specific containment controls that are required for the following:

  • Laboratory practices
  • Safety equipment
  • Facility construction

What are risk groups?

Risk groups are classify biological agents based on risk to humans. Biological agents are classified in a graded fashion. Risk groups range from RG1 - the lowest risk to RG4 - the highest risk.

  • RG1 – Are not associated with disease in healthy adult humans or animals
  • RG2 – Are associated with disease which is rarely serious and for which preventative or therapeutics is often available
  • RG3 – Are associated with serious or lethal human disease for which preventative or therapeutics may be available
  • RG4 – Are associated with lethal human disease for which preventative or therapeutics are not readily available

A protocol needs to be submitted if you will be conducting research, teaching, or testing for which you need to obtain or use live animals (all warm and cold-blooded vertebrates). If you are only doing in vitro work you do not need to submit a protocol.

Does the IBC work with other compliance committees? 

If there is a need for review by multiple compliance committees (e.g., IRB, SCRO and IACUC), the IBC will work with the other committees to ensure those approvals are in place.  IBC approval does not supersede or waive the requirement for independent review by other research compliance committees.

Do I need to complete an annual review?

Annually, Principal Investigators will receive a reminder email for their approved IBC Registration(s), requiring them to complete an annual review. This activity helps the PI remain compliant and aids in determining if major changes have been made to the registration that have not yet been approved.